Medarex/Bristol's Ipilimumab Shows Off Long-Term Survival Data At ASCO
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Two-year melanoma survival data from three Phase II studies of Medarex/Bristol-Myers Squibbs' immunotherapeutic ipilimumab presented at the American Society of Clinical Oncology meeting May 31 bode well for an ongoing pivotal Phase III study and an eventual first approval for the oncologic